Companies /Healthcare

Natera Inc

NASDAQ: NTRA Diagnostics & Research
$328.93
▲ $2.79 (+0.86%) today
Markets closed · 4:26am ET

Q3 2025 Earnings

Reported Nov 6, 2025, 4:08pm ET · SEC source
$-0.64
Miss −80.74%
EPS · est. $-0.35
$592.2M
Beat +15.04%
Revenue · est. $514.8M
+14.4%
Beating market
NTRA vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0+3%Nov 6Nov 7report 4:08pm ETearnings+0.1%−2.2%
−6%−3%0+3%Nov 6Nov 7earnings+0.1%−2.2%
NTRA −2.2%S&P 500 +0.1%
−6%−3%0+3%Nov 6Nov 7report 4:08pm ETearnings−0.3%−2.2%
−6%−3%0+3%Nov 6Nov 7earnings−0.3%−2.2%
NTRA −2.2%NASDAQ −0.3%
−8%−4%0Nov 5Nov 14report 4:08pm ETearnings+0.1%−2.4%
−8%−4%0Nov 5Nov 14earnings+0.1%−2.4%
NTRA −2.4%S&P 500 +0.1%
−8%−4%0Nov 5Nov 14report 4:08pm ETearnings−0.5%−2.4%
−8%−4%0Nov 5Nov 14earnings−0.5%−2.4%
NTRA −2.4%NASDAQ −0.5%
+0.55%
Day of report
+3.54%
Next session
+2.36%
One week
+16.82%
30 days

S&P 500 over the same 30 days: +2.47%.

Did NTRA Beat Earnings? Q3 2025 Results

Natera posted a mixed third quarter, delivering a notable revenue beat while falling short on the bottom line, as aggressive investment in clinical programs weighed heavily on earnings. The genetic testing company reported Q3 2025 revenue of $592.18 million, clearing the $514.77 million consensus by 15.04% and growing 34.7% year-over-year, powered by strong oncology volume growth and average selling price improvements, including roughly $55.10 million in true-up revenue from prior-period cash collections. However, the earnings picture was considerably more troubled; Natera posted a net loss of $0.64 per share, missing the consensus estimate of $0.35 by 80.74%, as total operating expenses surged 54.9% year-over-year to $482.00 million amid accelerating R&D spending on early cancer detection and MRD programs. Despite the widening loss, the company generated approximately $59.40 million in operating cash flow and raised its full-year 2025 revenue guidance by $160.00 million at the midpoint to a range of $2.18 billion to $2.26 billion, signaling continued confidence in its commercial trajectory.

Key Takeaways
  • 35.3% increase in product revenues driven by volume growth and average selling price improvements
  • Cash receipts collected during the quarter in excess of initial revenue estimates for tests delivered in prior quarters ($55.1M in true-ups)
  • 53.9% year-over-year growth in oncology test volumes to approximately 211,000 tests
  • Record sequential clinical MRD unit growth of approximately 21,500 units over Q2 2025
  • Continued progress in reducing cost of revenues associated with tests processed
  • Strong performance in women's health
  • Organ health continues to expand including competitive wins

“Results in the third quarter were excellent, including our largest increase in quarterly clinical MRD units to date. We continue to advance innovation across the portfolio, with successful read-outs for Signatera™, positive new results for our early cancer detection program, and the announcement of an expanded panel for our Fetal Focus™ single-gene noninvasive prenatal test.”

Natera CEO, on the earnings call

Forward Guidance & Outlook

Natera raised its 2025 annual revenue guidance by $160 million at the midpoint to $2.18 billion–$2.26 billion, up from $2.02 billion–$2.10 billion. The company expects 2025 gross margin of approximately 62%–64% of revenues, SG&A costs of approximately $1.075 billion–$1.175 billion, R&D costs of approximately $575 million–$625 million, and net cash inflow of approximately $100 million.

NTRA YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$200.0M$400.0M$600.0M$439.8M$592.2MRevenue$271.7M$384.4MGross Profit
$0$200.0M$400.0M$600.0MRevenueGross Profit

NTRA Revenue by Segment

Product Revenues
Licensing and Other Revenues

Figures from SEC filings and company reports. Not investment advice.